Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	2,488	2,730	3,106	2,886	2,194
Short-Term Investments	6,524	8,115	4,636	2,809	1,393
Cash & Short-Term Investments	9,013	10,845	7,742	5,695	3,587
Cash Growth	-16.90%	40.07%	35.96%	58.76%	11.60%
Accounts Receivable	5,844	5,299	5,023	5,059	3,112
Other Receivables	367.8	368.5	305.6	977.5	1,003
Receivables	6,212	5,667	5,329	6,037	4,115
Inventory	3,087	2,581	2,402	1,951	1,917
Prepaid Expenses	348.4	386.6	411.2	332.4	160.8
Restricted Cash	0.8	-	-	-	-
Total Current Assets	18,661	19,479	15,884	14,015	9,779
Property, Plant & Equipment	4,817	4,224	3,834	3,482	3,222
Long-Term Investments	9,060	5,471	6,640	6,878	3,195
Other Intangible Assets	1,149	1,039	915.5	6.7	-
Long-Term Deferred Tax Assets	3,314	2,575	1,724	876.9	858.9
Other Long-Term Assets	758.8	291.8	216.9	176.1	108.9
Total Assets	37,759	33,080	29,215	25,435	17,163
Accounts Payable	789.5	606.6	589.2	564	475.5
Accrued Expenses	2,497	2,339	2,054	1,593	1,609
Current Portion of Leases	30.3	19	12.4	719.7	-
Current Income Taxes Payable	-	-	-	326.3	19.5
Current Unearned Revenue	627.7	458.9	485.3	442	577.7
Other Current Liabilities	-	-	-	287.4	16.1
Total Current Liabilities	3,944	3,423	3,141	3,933	2,697
Long-Term Debt	1,984	1,983	1,981	1,980	1,979
Long-Term Leases	924.1	788.7	775.8	-	717.2
Long-Term Unearned Revenue	185.7	126.7	69.8	73.3	57.8
Other Long-Term Liabilities	1,367	785.4	582.2	680.2	687.1
Total Liabilities	8,406	7,107	6,551	6,666	6,138
Common Stock	0.1	0.1	0.1	0.1	0.1
Additional Paid-In Capital	12,856	11,354	9,949	8,088	6,716
Retained Earnings	31,673	27,260	23,307	18,968	10,893
Treasury Stock	-15,167	-12,560	-10,353	-8,261	-6,613
Comprehensive Income & Other	-7.9	-80.9	-238.8	-26.2	29.3
Shareholders' Equity	29,354	25,973	22,664	18,769	11,025
Total Liabilities & Equity	37,759	33,080	29,215	25,435	17,163
Total Debt	2,939	2,791	2,770	2,700	2,696
Net Cash (Debt)	14,974	13,451	11,565	9,833	4,027
Net Cash Growth	11.32%	16.31%	17.61%	144.18%	-30.05%
Net Cash Per Share	130.09	118.30	101.89	87.64	34.99
Filing Date Shares Outstanding	107.02	107.46	106.73	106.44	104.14
Total Common Shares Outstanding	107.3	107.12	107	106.57	103.96
Working Capital	14,717	16,056	12,743	10,082	7,082
Book Value Per Share	273.57	242.47	211.81	176.11	106.05
Tangible Book Value	28,205	24,935	21,749	18,762	11,025
Tangible Book Value Per Share	262.86	232.78	203.26	176.05	106.05
Land	288.2	283.1	264.5	248	241.2
Buildings	2,573	2,423	2,270	2,089	1,891
Machinery	2,149	1,940	1,803	1,662	1,395
Construction In Progress	1,722	1,345	980.5	767.7	724.5
Leasehold Improvements	154.5	133.9	114.3	113.9	100.5

Source: S&P Capital IQ. Standard template. Financial Sources.